2010
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers. Journal Of Clinical Oncology 2010, 28: 4316-4323. PMID: 20805453, DOI: 10.1200/jco.2009.27.2419.Peer-Reviewed Original ResearchMeSH KeywordsAmyloid beta-Protein PrecursorAntineoplastic Agents, HormonalBiopsy, Fine-NeedleB-LymphocytesBreast NeoplasmsChi-Square DistributionCollagen Type IVExtracellular Matrix ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMetagenomeNeoplasm Recurrence, LocalPhospholipid Transfer ProteinsPrognosisProportional Hazards ModelsProspective StudiesProtease NexinsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Cell SurfaceReceptors, EstrogenReceptors, Transforming Growth Factor betaSurvival AnalysisTamoxifenConceptsER-negative cancersBreast cancer stromaER-positive cancersPrognostic valueCancer stromaNegative cancersProliferative cancersSystemic adjuvant therapyTamoxifen-treated patientsNode-negative patientsEstrogen-receptor positiveStrong prognostic valueCore needle biopsySubset of tumorsLess prognostic valueDistant relapseAdjuvant therapyHazard ratioFavorable prognosisHighest tertilePrognostic scoreCore biopsyBreast cancerImmune functionMultivariate analysisGenomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. Journal Of Clinical Oncology 2010, 28: 4111-4119. PMID: 20697068, PMCID: PMC2953969, DOI: 10.1200/jco.2010.28.4273.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionDisease-Free SurvivalEstrogen Receptor alphaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenomicsHumansMiddle AgedNeoplasm StagingOligonucleotide Array Sequence AnalysisPatient SelectionProportional Hazards ModelsRisk AssessmentRisk FactorsSurvival AnalysisTamoxifenTime FactorsTranscription, GeneticTreatment OutcomeConceptsAdjuvant endocrine therapyEndocrine therapyBreast cancerDistant relapseER-positive breast cancerChemo-endocrine therapyDistant relapse riskYears of tamoxifenAdjuvant systemic therapyEstrogen receptor αBreast cancer samplesPrior chemotherapyNeoadjuvant chemotherapyPathologic responseSurvival benefitSystemic therapyUntreated cohortRelapse riskDeath riskTherapy indexAromatase inhibitionESR1 levelsReceptor αTamoxifenTherapy
2007
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Annals Of Oncology 2007, 19: 315-320. PMID: 17804473, DOI: 10.1093/annonc/mdm429.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBiomarkers, TumorBreast NeoplasmsChi-Square DistributionCohort StudiesCombined Modality TherapyDisease-Free SurvivalErbB ReceptorsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedNeoplasm StagingPredictive Value of TestsProbabilityProportional Hazards ModelsProto-Oncogene Proteins c-aktRandomized Controlled Trials as TopicReceptor, ErbB-2Risk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly breast cancerBreast cancerPredictive valuePhosphorylated AktAdjuvant chemotherapyPAkt expressionAnthracycline-based adjuvant chemotherapyEarly-stage breast cancerEpidermal growth factor receptor expressionGrowth factor receptor expressionAkt phosphorylationBreast cancer tissuesFactor receptor expressionGrowth factor receptorHER2 tumorsRandomized trialsAssessable tumorsHER2 expressionReceptor expressionPositive stainingCancer tissuesEGFR expressionHER2Tumor resistancePatients